Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Triple Negative Breast Cancer
Phase NA
Enrollment 115
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

The aim of our study is to find the best imaging technique, alone or in combination, that can best predict a complete response (absence of tumour cells). It also seems important to identify blood markers able to predict which patients will benefit most from treatment, with a view to personalising them, or which patients will be most at risk of toxicities, particularly related to immunotherapy, with a view to personalising monitoring.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Other: Imaging assessment — The patient will have four imaging exam : Ultrasound, angio/mammography, MRI and PET-scan

Primary Outcomes

  • concordance rate between quadrimodal radiological assessment (ultrasound, angiography/mammography, MRI, PET-CT) and histologically-obtained response following neoadjuvant chemo-immunotherapy in patients with triple-negative breast cancer (TNBC). (two weeks after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-28
Completion: 2029-11-28
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 115 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Henri Becquerel
Principal Investigators:
  • Florian Clatot, Md, PhD (PRINCIPAL_INVESTIGATOR) - Centre Henri Becquerel
Contact Information
Study Contact:
Florian Clatot, MD, PhD
+33276673004
florian.clatot@chb.unicancer.fr
Doriane Richard, PhD
+33232082985
doriane.richard@chb.unicancer.fr
Florian Clatot, MD, PhD
+33276673004
florian.clatot@chb.unicancer.fr
Centre Henri Becquerel
Interventions
  • Other: Imaging assessment — The patient will have four imaging exam : Ultrasound, angio/mammography, MRI and PET-scan
Study Locations (1 sites)
Centre Henri Becquerel, Rouen, 76038 France
Eligibility Criteria
Inclusion Criteria: * Signed informed consent * Patient with histologically proven TNBC * Indication for neo-adjuvant chemo-immunotherapy treatment * Age between 18 and 75 * Affiliated or beneficiary of a social protection scheme Exclusion Criteria: * Pregnant or breast-feeding women * Contraindication to immunotherapy * Inflammatory breast cancer (T4d) * Metastatic patients * Allergies to iodine or gadolinium * Patient with an augmentation prosthesis (for angiography/mammography) * Claustrophobic patients * Renal contraindication to contrast products according to SFR-CIRTACI * Ferromagnetic material * Uncontrolled diabetes (blood glucose \>10 mmol/L) * Patient unable to understand the study for any reason or to comply with the constraints of the trial (language, psychological, geographical problems, etc.). * Patient under guardianship, curatorship or safeguard of justice
Conditions HER2-positive Breast Cancer
Phase PHASE2
Enrollment 53
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of the study is to find out if an investigational drug called Dendritic Cell (DC1) vaccine added to standard neoadjuvant (given before main treatment) therapy can help people with HER2 (human epidermal growth factor receptor 2) positive breast cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: HER-2 pulsed DC1 — Vaccine will be administered weekly for 6 weeks. Boosters will be given at months 6, 9 and 12.
  • Drug: Trastuzumab — 8mg/kg IV Trastuzumab will be given week 1, followed by 6 mg/kg on subsequent cycles every 3 weeks
  • Drug: Pertuzumab — 840 mg IV Pertuzumab will be given week 1, followed by 420 mg on subsequent cycles every 3 weeks.
  • Drug: Paclitaxel — 80 mg/m\^2 IV paclitaxel will be given weekly weeks 7-18
  • Procedure: Resection surgery — After week 18, participants will undergo standard of care resection surgery.

Primary Outcomes

  • Lead in Phase: Immunogenicity of each dose level (at 4 weeks)
  • Expansion Phase: Pathologic Complete Response Rate (at 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2021-10-28
Completion: 2027-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 53 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Collaborators: ImmunoRestoration
Principal Investigators:
  • Hyo (Heather) Han, MD (PRINCIPAL_INVESTIGATOR) - Moffitt Cancer Center
Contact Information
Study Contact:
Neveen Abdo
813-745-4412
Neveen.Abdo@moffitt.org
Hyo Han, MD
Moffitt Cancer Center
Avan Armaghani, MD
Moffitt Cancer Center
Interventions
  • Biological: HER-2 pulsed DC1 — Vaccine will be administered weekly for 6 weeks. Boosters will be given at months 6, 9 and 12.
  • Drug: Trastuzumab — 8mg/kg IV Trastuzumab will be given week 1, followed by 6 mg/kg on subsequent cycles every 3 weeks
  • Drug: Pertuzumab — 840 mg IV Pertuzumab will be given week 1, followed by 420 mg on subsequent cycles every 3 weeks.
  • Drug: Paclitaxel — 80 mg/m\^2 IV paclitaxel will be given weekly weeks 7-18
  • Procedure: Resection surgery — After week 18, participants will undergo standard of care resection surgery.
Study Locations (1 sites)
Moffitt Cancer Center, Tampa, Florida 33612 United States
Eligibility Criteria
Inclusion Criteria: * Participants must have histologically confirmed clinical stage I- III, HER2+ (per ASCO/CAP criteria) invasive carcinoma of the breast. Primary tumor should measure at least 1 cm by clinical exam or radiologic tests * Candidate for neoadjuvant chemotherapy with Paclitaxel, Trastuzumab, Pertuzumab regimen followed by standard of care local therapy as determined by the treating physician * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Participants must have normal organ and marrow function as defined per protocol. * Cardiac ejection fraction within institutional normal limits by either Multigated Acquisition Scan (MUGA) or Echocardiogram at baseline. * Women of child-bearing potential and their male partners must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Sexually active male participants should use a barrier method or exercise abstinence during chemotherapy administration until surgery. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Participants with inflammatory breast cancer, widespread locally advanced unresectable disease involving the chest wall/nodal basins in which a curative surgical resection cannot be performed, or those in whom de novo metastatic disease is suspected or confirmed. * Patients may not be receiving any other investigational agents for the treatment of their breast cancer. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study vaccine components and any of the chemotherapy drugs (paclitaxel, trastuzumab, pertuzumab). * Participants who are unwilling or unable to undergo an apheresis for production of their vaccine. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant women and women who are breastfeeding. * Participants with known congenital or acquired immune deficiency (including those patients who require systemic immunosuppressant drugs for autoimmune disease or organ transplant).
Conditions Breast Masses, Breast Cancer, Breast Can...
Phase NA
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

Photoacoustic (PA) imaging (PAI) emergerd as a rapidly evolving biomedical imaging modality, which combines the merits of optical imaging and ultrasound (US) imaging, and has a capacity in morphological, functional and molecular imaging, showing potential in visualizing superficial organs. The goal of this clinical trial is to build a PAI standardized scoring system to identify benign and malignant tumors, and use PAI to further determine the molecular classification of malignant breast tumors, and monitor the efficacy of neoadjuvant chemotherapy (NAC) in breast cancer. The main questions it aims to answer are: 1. How to build a standardized PA/US scoring system in differential diagnosis of benign and malignant tumors? 2. Can PAI precisely determine the molecular classification of breast tumors? 3. Can PAI systems predict the efficacy of NAC in breast cancer? Participants will receive regular PA/US imaging examinations during four stages of NAC (before NAC, 2 Cycles, 4 Cycles and 6 Cycles). And the effectiveness of PA/US in predicting NAC for breast cancer at different time points will be evaluated.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Diagnostic Masking/blinding: Single

Interventions / Regimen

  • Diagnostic Test: Multi-modal photoacoustic/ultrasonic (PA/US) imaging system — The multi-modal PA/US imaging system is equipped with a handheld PA/US probe, and able to provide data of dual-wavelength PA imaging of breat tomor and Ipsilateral axillary lymph nodes, in addition to real-time 2D PA/US imaging.

Primary Outcomes

  • Establish Photoacoustic/Ultrasound Standardized Scoring System for Differentiating Benign and Malignant Breast Masses (From enrollment to the end of treatment at 2 year)
  • Predict the Precise Molecular Subtypes of Malignant Breast Masses Using Photoacoustic/Ultrasound Parameters (From enrollment to the end of treatment at 2 years)
  • Evaluate Tumor Residual and Lymph Node Burden in Breast Cancer after Neoadjuvant Therapy (From enrollment to the end of treatment at 3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-06-12
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking Union Medical College Hospital
Contact Information
Study Contact:
Meng Yang, Doctor
8601060155493
yangmeng_pumch@126.com
Meng Yang, Doctor
8601069155493
yangmeng_pumch@126.com
Peking Union Medical College Hospital
Interventions
  • Diagnostic Test: Multi-modal photoacoustic/ultrasonic (PA/US) imaging system — The multi-modal PA/US imaging system is equipped with a handheld PA/US probe, and able to provide data of dual-wavelength PA imaging of breat tomor and Ipsilateral axillary lymph nodes, in addition to real-time 2D PA/US imaging.
Study Locations (1 sites)
Peking Union Medical College Hospital, Beijing, Beijing Municipality 100730 China
Eligibility Criteria
Inclusion Criteria: 1. The patients were above 18 years-old; 2. The patients were presented with a breast tumor, which were clearly shown on routine ultrasound; Biopsy or surgery of breast lesions was performed within 1 week and pathological diagnosis was obtained. 3. Patients agreed to participate in this experiment and signed the Subject Informed Consent. Exclusion Criteria: 1. Pregnant or lactating women; 2. Breast inflammation or local external injury; 3. The breast mass has been excised for biopsy. 4. Poor photoacoustic imaging effect. 5. Deep lesion location (\>3.5 cm)
Conditions Breast Neoplasms, Breast Cancer
Phase PHASE2
Enrollment 372
Locations 17 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. The main goals of this study are to learn: * About the safety of the study treatments and if people tolerate them * If people who receive patritumab deruxtecan, pembrolizumab, and chemotherapy before surgery have fewer cancer cells removed during surgery compared to those who receive only pembrolizumab (pembro) and chemotherapy.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: Patritumab deruxtecan — Administered via IV infusion as neoadjuvant treatment
  • Biological: Pembrolizumab — Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2
  • Drug: Paclitaxel — Administered via IV infusion as neoadjuvant treatment
  • Drug: Carboplatin — Administered via IV infusion as neoadjuvant treatment
  • Drug: Doxorubicin hydrochloride — Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
  • Drug: Epirubicin hydrochloride — Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
  • Drug: Cyclophosphamide — Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
  • Drug: Capecitabine — Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2

Primary Outcomes

  • Part 1: Number of Participants Experiencing an Adverse Event (AE) (Up to ~43 weeks)
  • Part 1: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) (Up to 21 days)
  • Part 1: Number of Participants who Discontinued Study Treatment Due to an AE (Up to ~30 weeks)
  • Part 2: Pathological Complete Response (pCR) Rate Using the Definition of ypT0/Tis ypN0 (Up to ~30 weeks)
  • Part 2: Number of Participants Experiencing an AE (Up to ~103 weeks)
  • Part 2: Number of Participants who Discontinued Study Treatment Due to an AE (Up to ~90 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-03-20
Completion: 2034-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 372 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Merck Sharp & Dohme LLC
Collaborators: Daiichi Sankyo
Principal Investigators:
  • Medical Director (STUDY_DIRECTOR) - Merck Sharp & Dohme LLC
Contact Information
Study Contact:
Toll Free Number
1-888-577-8839
Trialsites@msd.com
Study Coordinator
424-402-9520
UCLA Hematology/Oncology - Parkside ( Site 0021)
Study Coordinator
847-568-9932
Orchard Healthcare Research Inc. ( Site 0006)
Interventions
  • Biological: Patritumab deruxtecan — Administered via IV infusion as neoadjuvant treatment
  • Biological: Pembrolizumab — Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2
  • Drug: Paclitaxel — Administered via IV infusion as neoadjuvant treatment
  • Drug: Carboplatin — Administered via IV infusion as neoadjuvant treatment
  • Drug: Doxorubicin hydrochloride — Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Study Locations (17 sites)
UCLA Hematology/Oncology - Parkside ( Site 0021), Santa Monica, California 90404 United States
Orchard Healthcare Research Inc. ( Site 0006), Skokie, Illinois 60077 United States
Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0003), Billings, Montana 59102 United States
Northwest Cancer Specialists (Compass Oncology) ( Site 8003), Tigard, Oregon 97223 United States
SCRI Oncology Partners ( Site 7000), Nashville, Tennessee 37203 United States
Texas Oncology - DFW ( Site 8000), Dallas, Texas 75246 United States
Houston Methodist Hospital ( Site 0022), Houston, Texas 77030 United States
Virginia Oncology Associates (VOA) ( Site 8001), Norfolk, Virginia 23502 United States
Seoul National University Hospital ( Site 2400), Seoul, 03080 South Korea
Severance Hospital, Yonsei University Health System ( Site 2402), Seoul, 03722 South Korea
Eligibility Criteria
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has locally advanced, non-metastatic (M0), breast cancer, defined as any of the following combined primary tumor (T) and regional lymph node (N) staging per current American Joint Committee on Cancer (AJCC) criteria: cT1c, N1-N2; cT2, N0-N2; cT3, N0-N2; or cT4a-d, N0-N2 * Has centrally confirmed diagnosis of breast cancer that is triple-negative or HR-low+/HER2- breast cancer that will be treated according to the triple-negative breast cancer (TNBC) paradigm * Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load * Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 28 days prior to allocation/randomization * Has left ventricular ejection fraction (LVEF) of ≥50% or ≥ lower limit of normal (LLN) as assessed by echocardiogram (ECHO) or multigate acquisition scan (MUGA) scan Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has uncontrolled or significant cardiovascular disease before randomization * Has any history of or evidence of any current leptomeningeal carcinomatosis. * Has clinically significant corneal disease * Has human immunodeficiency virus (HIV) infection with a history of Kaposi sarcoma and/or multicentric Castleman disease * Has evidence of ongoing, uncontrolled, systemic bacterial, fungal, or viral infection * Has received prior therapy with an anti-programmed death (PD)-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor * Has received any prior treatment, including radiation, systemic therapy, and/or definitive surgery for currently diagnosed breast cancer * Has received prior treatment with an anti-human epidermal growth factor receptor 3 (HER3) antibody and/or antibody-drug conjugate (ADC) that consists of an exatecan derivative that is a topoisomerase I inhibitor (e.g., trastuzumab deruxtecan) * Has metastatic (Stage IV) breast cancer or cN3 nodal involvement * Has known additional malignancy that is progressing or has required active treatment within the past 5 years * Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis * Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use, or current or suspected ILD * Has an active infection requiring systemic therapy * Has concurrent active HBV and HCV infection * Has clinically severe respiratory compromise resulting from intercurrent pulmonary illness
Conditions TNBC, Triple Negative Breast Cancer
Phase PHASE2
Enrollment 34
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

This study is a single-arm, multicenter, prospective phase II clinical trial designed to evaluate the efficacy and safety of QL1706 in combination with anlotinib hydrochloride and nab-paclitaxel as first-line treatment for advanced triple-negative breast cancer. A total of 34 participants with first-line advanced triple-negative breast cancer are enrolled in this study: Enrolled participants receive QL1706 (5 mg/kg, Q3W, day 1) + anlotinib (12 mg per dose, QD, days 1-14, Q3W) + nab-paclitaxel (125 mg/m², days 1 and 8, Q3W), with a 21-day cycle. Treatment continues until disease progression, intolerable toxicity, the investigator's judgment that the participant no longer derives benefit, withdrawal of informed consent by the participant, completion of 2 years of QL1706 treatment, or other reasons specified in the protocol. The study consists of a screening period (from the signing of informed consent to no more than 28 days before the first dose), a treatment period (including on-treatment visits and end-of-treatment visit), and a follow-up period (including safety follow-up and survival follow-up). Screening Period: The screening period begins after the participant signs the informed consent form and ends at enrollment, lasting no more than 28 days. Eligible participants are those with pathologically confirmed, previously untreated first-line triple-negative breast cancer. During screening, participant information, samples, and blood specimens are collected as needed. Participants who meet all inclusion criteria and none of the exclusion criteria are enrolled. Treatment Period: Study drugs are administered within 3 days of enrollment. Each treatment cycle is 3 weeks. Study treatment continues until disease progression, intolerable toxicity, initiation of new anti-cancer therapy, loss to follow-up, death, withdrawal of informed consent, or other reasons, with a maximum treatment duration of 2 years (whichever occurs first). Safety assessments are performed every 3 weeks, and tumor imaging evaluations are performed every 6 weeks (±7 days) according to RECIST v1.1 criteria. Follow-up Period: When participants discontinue study treatment or withdraw early, they are still required to complete the corresponding assessments as specified in the protocol. Safety Follow-up: At 30 days (±7 days) after the last dose, participants return to the site for one follow-up visit, during which blood samples are collected and safety examinations are performed. Survival Follow-up: Every 2 months. Survival status and subsequent treatment information are collected by telephone or other appropriate means.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: TREATMENT GROUP(QL1706 + anlotinib+ nab-paclitaxel ) — QL1706 (5 mg/kg, Q3W, day 1) + anlotinib (12 mg per dose, QD, days 1-14, Q3W) + nab-paclitaxel (125 mg/m², days 1 and 8, Q3W), with a 21-day cycle

Primary Outcomes

  • PFS (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-04-17
Completion: 2027-09-15
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 34 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jiangsu Cancer Institute & Hospital
Contact Information
Study Contact:
Lili Zhang
+86 13951004558
lilizhang208ky@163.com
Yuan Yuan
86 13851588800
yuanyuan810122@126.com
Lili Zhang
+86 13951004558
lilizhang208ky@163.com
Jiangsu Cancer Hospital
Interventions
  • Drug: TREATMENT GROUP(QL1706 + anlotinib+ nab-paclitaxel ) — QL1706 (5 mg/kg, Q3W, day 1) + anlotinib (12 mg per dose, QD, days 1-14, Q3W) + nab-paclitaxel (125 mg/m², days 1 and 8, Q3W), with a 21-day cycle
Study Locations (1 sites)
Jiangsu Cancer Hospital, Nanjing, Jiangsu China
Eligibility Criteria
Inclusion Criteria: 1. Participants voluntarily join the study, sign the informed consent form, and agree to strictly comply with the study protocol requirements. 2. Female patients aged between 18 and 75 years. 3. Confirmed by histopathological examination as advanced triple-negative invasive breast cancer, meeting the following criteria: pathological type triple-negative, specifically: ER negative (IHC \<1%), PR negative (IHC \<1%), HER2 negative (IHC -/+ or IHC ++ but FISH/CISH negative). Priority is given to pathology from metastatic lesions; if metastatic lesion pathology is not available, primary lesion pathology may be used. 4. TNBC patients with initial diagnosis of stage IV (according to AJCC 8th edition) or recurrent/metastatic disease who are not suitable for surgery, and have not received prior systemic therapy for advanced disease. Prior neoadjuvant and/or adjuvant therapy with taxanes or other anti-tumor treatments is permitted, provided that there was no disease progression during neoadjuvant therapy, and the interval between completion of taxane-based (neo)adjuvant therapy and recurrence/metastasis is ≥6 months. 5. Suitable for nab-paclitaxel treatment. 6. At least one measurable tumor lesion according to RECIST 1.1 criteria. 7. Expected survival ≥3 months. 8. ECOG performance status 0 or 1. 9. Adequate organ function, including: 1)Hematology: Absolute neutrophil count (ANC) ≥1.5×10⁹/L; platelet count (PLT) ≥100×10⁹/L; hemoglobin (HB) ≥90 g/L. 2)Liver function: Total bilirubin ≤1.5×ULN; AST and ALT ≤2.5×ULN; if liver metastases are present, ALT and AST must be ≤5×ULN. 3)Renal function: Serum creatinine (Cr) ≤1.5×ULN, or creatinine clearance ≥60 mL/min (calculated by the Cockcroft-Gault formula). 10.Participants of childbearing potential must use appropriate contraception during the study and for 120 days after study completion, have a negative serum pregnancy test within 7 days before study enrollment, and must not be lactating. Exclusion Criteria: 1. Known history of severe allergic reactions to QL1706, anlotinib, nab-paclitaxel, or any of their excipients. 2. Inability to swallow oral medications, or any gastrointestinal disorder that may interfere with the absorption and metabolism of the study drugs. 3. Symptomatic brain/leptomeningeal metastases and/or spinal cord metastases. 4. Active or potentially relapsing autoimmune disease, with the following exceptions: vitiligo, alopecia, psoriasis, or eczema not requiring systemic treatment; hypothyroidism due to autoimmune thyroiditis requiring only stable-dose hormone replacement therapy; type I diabetes mellitus requiring only stable-dose insulin replacement therapy. 5. Major surgery within 3 weeks before study initiation, or failure to recover from surgery. 6. History of organ transplantation or autologous/allogeneic stem cell transplantation. 7. Known or self-reported human immunodeficiency virus (HIV) infection. 8. HBV-DNA positive or HCV-DNA positive (copy number \>10³). 9. Prior treatment with any agent targeting the mechanism of tumor immunotherapy, including immune checkpoint inhibitors (e.g., anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-CTLA-4 antibodies), immune checkpoint agonists (e.g., antibodies targeting ICOS, CD40, CD137, GITR, OX40), or immune cell therapy. 10. Prior treatment with anti-angiogenic targeted therapy. 11. Hypertension that cannot be well controlled with a single antihypertensive medication (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥90 mmHg). 12. Arterial/venous thrombotic events (e.g., cerebrovascular accident including transient ischemic attack, deep vein thrombosis, pulmonary embolism) within 6 months before enrollment. 13. Presence of other malignancies within 5 years before enrollment, except for TNBC. 14. Tumor invasion or compression of surrounding major blood vessels or organs. 15. Active central nervous system (CNS) metastatic lesions. 16. Clinically significant pleural effusion, pericardial effusion, or ascites requiring repeated drainage. 17. History of myocarditis, cardiomyopathy, or malignant arrhythmias. 18. History of significant bleeding tendency or coagulation dysfunction. 19. History of esophageal-gastric varices, severe ulcer, non-healing wound, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding within 6 months before the first dose. 20. Known active tuberculosis (TB). 21. History of or current non-infectious pneumonitis/interstitial lung disease requiring systemic corticosteroid therapy. 22. Major surgery or severe trauma within 30 days before the first dose, or planned major surgery within 30 days after the first dose; minor local surgery within 3 days before the first dose. 23. Platelet or red blood cell transfusion within 4 weeks before initiation of study drug treatment. 24. Receipt of live vaccine within 4 weeks before the first dose, or planned receipt of live vaccine during the study. 25. Female participants who are pregnant, breastfeeding, or planning to become pregnant during the study. 26. Patients judged by the investigator to be unsuitable for participation in this study.
Conditions Metastatic Breast Cancer, Brain Metastas...
Phase PHASE1, PHASE2
Enrollment 41
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

Patients with metastatic breast cancer with at least 2 brain metastases will receive pembrolizumab every 3 weeks. Patients will undergo stereotactic radiosurgery (SRS) to one of the brain lesions. Pembrolizumab infusion will be given on Day 4 (+/-1) after SRS treatment at the standard dose of 200mg IV over 30 minutes and repeated every 3 weeks until disease progression or unacceptable toxicity.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Pembrolizumab — Pembrolizumab infusion will be given on Day 4 (+/-1) after SRS treatment at the standard dose of 200mg IV over 30 minutes and repeated every 3 weeks until disease progression or unacceptable toxicity.

Primary Outcomes

  • Tumor response for non-irradiated brain lesions at 8 weeks according to RECIST1.1 (8 weeks)
  • Correlation of abscopal responses with the radiation dose received (1 year)
  • Overall survival - assessed from the start of study drug until death in non-irradiation metastases in the rest of the body by routine imaging. (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2018-11-15
Completion: 2030-12-31
Eligibility
Age: 19 Years – 90 Years
Sex: FEMALE
Volunteers: false
Enrollment: 41 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Weill Medical College of Cornell University
Collaborators: Merck Sharp & Dohme LLC
Principal Investigators:
  • Silvia Formenti, M.D. (PRINCIPAL_INVESTIGATOR) - Weill Cornell Medicine - New York Presbyterian Hospital
Contact Information
Study Contact:
Fabiana Gregucci, M.D.
646-962-3110
fgr4002@med.cornell.edu
Fabiana Gregucci, M.D.
646-962-3110
fgr4002@med.cornell.edu
Weill Cornell Medicine
Izael Nino, M.S.
929-470-9426
izn4001@med.cornell.edu
Brooklyn Methodist Hospital - NewYork Presbyterian
Interventions
  • Drug: Pembrolizumab — Pembrolizumab infusion will be given on Day 4 (+/-1) after SRS treatment at the standard dose of 200mg IV over 30 minutes and repeated every 3 weeks until disease progression or unacceptable toxicity.
Study Locations (3 sites)
Weill Cornell Medicine, New York, New York 10065 United States
Brooklyn Methodist Hospital - NewYork Presbyterian, New York, New York 11215 United States
New York Presbyterian Hospital - Queens, New York, New York 11355 United States
Eligibility Criteria
Inclusion Criteria: * Age older than 18 * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Men and/or pre- or post-menopausal women with metastatic breast cancer with at least 2 intracranial untreated and measurable (≥ 3mm) metastases as visualized on brain MRI * A diagnostic contrast enhanced MRI demonstrating at least 2 lesions in the brain, (≥3mm in size), performed within two weeks prior to treatment * Maximum diameter of treated lesions should be \<4cm in size * Have measurable disease based on RECIST 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions. * Patient needs to be able to understand and demonstrate willingness to sign a written informed consent document * Prior SRS is permitted, however the lesions targeted for treatment on trial need to be previously untreated by SRS * Patients who have undergone prior subtotal resection are eligible providing that residual disease is \<4cm in maximum diameter: the cavity will be treated as standard of care. * Continuing a concurrent use of hormonal therapy or anti-Her2 neu therapy is allowed, if the patient exhibits brain metastases progression during these treatments * Enrolled patients should have a two-week washout period from last systemic treatment * The participant (or legally acceptable representative if applicable) provides written informed consent for the trial. * Contraception duration of 120 days * Adequate bone marrow reserve and liver function Exclusion Criteria: * Active connective tissue disorders, such as lupus or scleroderma requiring flare therapy * Patients who have undergone complete resection of all known brain metastases * Inability to obtain histologic proof of breast cancer * Target lesion metastasis within 5mm of the optic apparatus so that some portion of the optic nerve or chiasm would be included in the SRS field * Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease. * Has received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of study drug. Administration of killed vaccines is allowed. * Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment. * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug. * Has a known additional malignancy (second primary) that is progressing or has required active treatment within the past 3 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. cervical cancer in situ) that have undergone potentially curative therapy are not excluded. * Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients. * Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. * Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis. * Has an active infection requiring systemic therapy..Has a known history of Human Immunodeficiency Virus (HIV). * Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \[HBsAg\] reactive) or known active Hepatitis C virus (defined as HCV RNA \[qualitative\] is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority. * Has a known history of active TB (Bacillus Tuberculosis). * Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. * Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.
Conditions Triple Negative Breast Neoplasms
Phase PHASE2
Enrollment 53
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

This trial is a multicenter, single-arm clinical trial to evaluate the efficacy and safety of UTD1 in combination with capecitabine for the adjuvant treatment of TNBC patients who did not achieve pathologic complete remission after neoadjuvant therapy. TNBC patients who did not achieve pathological complete remission or positive lymph node after neoadjuvant chemotherapy received adjuvant treatment with study drug. Solution: UTD1 30mg / m², once a day on days 1-5; capecitabine: 1000mg / m², days 1-14, oral, twice / day; 21 days a treatment cycle of 6-8 cycles.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: UTD1 — UTD1: 30mg / m², once a day on days 1-5; capecitabine: 1000mg / m², days 1-14, oral, twice / day; 21 days a treatment cycle of 6-8 cycles.

Primary Outcomes

  • 2-year disease-free survival (DFS) (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-03-29
Completion: 2027-03-29
Eligibility
Age: 18 Years – 70 Years
Sex: FEMALE
Volunteers: false
Enrollment: 53 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hunan Cancer Hospital
Contact Information
Study Contact:
Quchang Ouyang
8673189762161
oyqc1969@126.com
Quchang Ouyang
8673189762161
oyqc1969@126.com
Quchang Ouyang
Interventions
  • Drug: UTD1 — UTD1: 30mg / m², once a day on days 1-5; capecitabine: 1000mg / m², days 1-14, oral, twice / day; 21 days a treatment cycle of 6-8 cycles.
Study Locations (1 sites)
Quchang Ouyang, Changsha, Hunan 410083 China
Eligibility Criteria
Inclusion Criteria: * Signed informed consent; * 18 Years and older; * Female; * Breast cancer confirmed by pathological histology, ER-negative (\<1% positive), PR-negative (\<1% positive), and HER2-negative (IHC: HER2 (0), HER2 (1+), or HER2 (2+) and FISH non-amplification; * Patients must receive full course of neoadjuvant chemotherapy before surgery and did not achieve pathological complete response (i. e., pathologically confirmed residual lesion, maximum diameter of 1cm) or / lymph node positive (ypN+); * Previous neoadjuvant chemotherapy regimen included anthracycline, taxane, or a combination of both. * Patients who clinically require radiotherapy of the affected breast or chest wall and regional lymph node area should receive radiotherapy before or after study medication; * All toxicities related to previous antitumor therapy must return to Grade 1 (CTCAE v5.0), except alopecia; * Within 1 week before enrollment, the blood routine examination was basically normal (taking the normal value of each study center as the standard): 1) Blood routine: hemoglobin (Hb) \> 90g / L, White blood cell count (WBC) \> 3.5\*10\^9 / L, Number of neutrophils (ANC) \* 1.5\*10\^9 / L, Platelet count (PLT)\* 100\*10\^9 / L; 2) Renal function: upper limit of normal serum creatinine value; 3) Liver function: for patients without liver metastasis: glutamulate aminotransferase (AST), glutamate aminotransferase (ALT), alkaline phosphatase (ALP) are less than 2.5 times of the upper limit of normal value, and totle bilirubin is less than 1.25 times of the upper limit of normal value; for patients with liver metastasis, AST, ALT, ALP, ALT, ALP, are less than 5 times of the upper limit of normal value, and totle bilirubin is less than 1.25 times of the upper limit of normal value; * The ECOG physical status score for patients must be 0 or 1; Exclusion Criteria: * Metastatic breast cancer at diagnosis; * Breast cancer patients who did not completed surgery; * History of other malignancies within 5 years prior to randomization, but patients with the following tumors may participate in the study: carcinoma of the cervix in situ, colon in situ, melanoma in situ and basal cell carcinoma of the skin and squamous cell carcinoma; * Any other non-malignant systemic disease (cardiovascular, renal, liver, etc.) that hinders the implementation or follow-up of the treatment program; * Symptomatic congestive heart failure (New York Heart Association Grade II-IV), symptomatic or poorly controlled arrhythmia, history of congenital long QT syndrome or corrected QTc\> 500ms at screening, history of uncontrolled hypertension or hypertensive crisis or hypertensive encephalopathy; * History of interstitial pneumonia, Need for steroids or evidence of active pneumonia; * Suffering from an active autoimmune disease, and required systemic treatment in the past 2 years (i. e., use of disease regulators, corticosteroids, or immunosuppressive drugs); * Patients with a known infection with human immunodeficiency virus (HIV); * Patients with active infections requiring systemic treatment; * Any hormonal medication (such as raloxifene, tamoxifen, or other selective oestrogen receptor modulators) for osteoporosis or breast cancer prophylaxis (only patients who have discontinued these drugs before randomization may participate in the study); * The patient received either capecitabine or utiderone before surgery; * Pregnant or lactating women; * Known or suspected allergy to any study drug or excipients; * Prohibition of corticosteroids; * Any other condition the investigator considers inappropriate to participate in the trial.
Conditions Breast Cancer
Phase Not Applicable
Enrollment 30000
Locations 134 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: MammaPrint, BluePrint, and Full-Genome Testing — Agendia will run MammaPrint and BluePrint tests using the full genome testing array.

Primary Outcomes

  • A large scale registry of full genome expression data to investigate new gene associations with prognostic and/or predictive value will be created. (10 years)
  • A shared registry infrastructure to examine smaller groups of interest. (10 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2017-04-28
Completion: 2037-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Agendia
Principal Investigators:
  • William Audeh, MD (STUDY_DIRECTOR) - Agendia, Inc.
  • Joyce O'Shaughnessy, MD (PRINCIPAL_INVESTIGATOR) - Texas Oncology - Baylor Charles A. Sammons Center
Contact Information
Study Contact:
Michelle Landon, MS, CGC
801-633-8215
michelle.landon@agendia.com
Nicolette Ziolkowski
NicoletteAnne.Ziolkowski@providence.org
Providence Alaska Medical Center
Theodore Kim
Providence Alaska Medical Center
Interventions
  • Diagnostic Test: MammaPrint, BluePrint, and Full-Genome Testing — Agendia will run MammaPrint and BluePrint tests using the full genome testing array.
Study Locations (134 sites)
CHS Grandview, Birmingham, Alabama 35243 United States
Providence Alaska Medical Center, Anchorage, Alaska 99508 United States
Arizona Oncology Associates, PC, Phoenix, Arizona 85006 United States
Arizona Oncology Associates, PC - HOPE, Tucson, Arizona 85704 United States
Adventist Health - Bakersfield, Bakersfield, California 93301 United States
Comprehensive Cancer Center at Desert Regional Medical Center, Palm Springs, California 92262 United States
North Valley Breast Clinic, Redding, California 96001 United States
UCSF Breast Care Center, San Francisco, California 94158 United States
Valley Breast Care, Van Nuys, California 91405 United States
Rocky Mountain Cancer Centers, Aurora, Colorado 80012 United States
Eligibility Criteria
Inclusion Criteria: * Stage I, II, or III patients who receive MammaPrint, with or without BluePrint testing (male or female) * Informed consent form signed on the same day or before enrollment * New primary lesion Exclusion Criteria: * Tumor sample shipped to Agendia with ≤ 30% tumor cells or that fails QA or QC criteria * Metastatic disease * Recurrent disease * Stage 0 disease
Conditions Stroke, Traumatic Brain Injury, Knee Ost...
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

The aging population and its accompanying burden from non-communicable chronic diseases predicts an increasing impact imposed by frailty on healthcare systems. This is due to a lack of normative data for older adults and reliable risk stratification methods to develop effective approaches to the prevention of frailty. In this study, the investigators plan to form a common dataset for phenotype identification, risk stratification of frailty and its targeted treatment plans in the at-risk and mildly frail population.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Incidence (rates) of Frailty (Through study's data collection period, up to 4 years)
  • Severity of Frailty (For inpatient: Visit 1 (within 2 weeks of admission) to Visit 6 (end of 3rd year); For outpatient: Visit 1 (baseline) to Visit 4 (end of 3rd year))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-01-01
Completion: 2027-01
Eligibility
Age: 50 Years and older
Sex: ALL
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tan Tock Seng Hospital
Collaborators: Rehabilitation Research Institute of Singapore (RRIS), Woodlands Health (WH)
Principal Investigators:
  • Karen Chua (PRINCIPAL_INVESTIGATOR) - Tan Tock Seng Hospital
Contact Information
Study Contact:
Low Ai Mei Jaclyn
68894580
Jaclyn_AM_LOW@ttsh.com.sg
Low Ai Mei Jaclyn
Jaclyn_AM_LOW@ttsh.com.sg
Tan Tock Seng Hospital
Interventions
N/A
Study Locations (1 sites)
Tan Tock Seng Hospital, Singapore, Singapore 308433 Singapore
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 50y 2. Asian ethnicity 3. First diagnosis (stroke, Traumatic Brain Injury (TBI), knee osteoarthritis, breast cancer) 4. Living in community 5. Able to understand 1 step simple commands 6. For inpatients: (i) within 12 weeks of disease (stroke/TBI) onset, and (ii) within 2 weeks of rehabilitation ward admission 7. For outpatients: (i) \>6 months from initial diagnosis of first stroke, TBI, knee osteoarthritis or breast cancer, and (ii) at least standby assistance, modified independent or independent in ambulation with /without walking. Exclusion Criteria: 1. Nursing home or dormitory resident 2. Non-resident status in Singapore (e.g. foreign worker, tourist, temporary visit pass) 3. Impairments affecting understanding of questionnaires and tasks: e.g. severe deafness, severe visual impairment and severe /global aphasia, 4. Presence of active fractures, dislocations, non-weight bearing status, burns, unhealed wounds, active skin infections/eczema and agitated behaviour or delirium 5. Anticipated life expectancy \< 1 year 6. Presence of tracheostomy, ventilator, renal dialysis, end-organ failure 7. Patients with disorders of consciousness. 8. Pregnant or lactating participants For Knee Osteoarthritis patients only: 9. Alternative diagnosis to knee OA e.g. Referred pain from hip or spine. 10. Other forms of knee arthritis eg. Inflammatory, post traumatic 11. Previous knee arthroplasty
Conditions Metastatic Breast Cancer, Lobular Breast...
Phase Not Applicable
Enrollment 150
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective observational registry for patients with invasive lobular carcinoma (ILC) of the breast. After the first 1cohort is enrolled, the collected data will be utilized to develop an ILC specific response assessment tool.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: Blood Specimen — Blood will be drawn via venipuncture

Primary Outcomes

  • Feasibility of registry (Up to 2 years)
  • Proportion of patients with measurable versus unmeasurable disease (Up to 10 years)
  • Median Progression Free Survival Rate (Up to 10 years)
  • Median Overall Survival Rates (Up to 10 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-12-20
Completion: 2036-02-28
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Francisco
Collaborators: METAvivor Research and Support, Inc
Principal Investigators:
  • Rita Mukhtar, MD (PRINCIPAL_INVESTIGATOR) - University of California, San Francisco
Contact Information
Study Contact:
Venezia Garza
415-353-8732
venezia.garza@ucsf.edu
Rebecca Shatsky, MD
University of California, San Diego
Venezia Garza
415-353-8732
venezia.garza@ucsf.edu
University of California, San Francisco
Interventions
  • Procedure: Blood Specimen — Blood will be drawn via venipuncture
Study Locations (4 sites)
University of California, San Diego, San Diego, California 92053 United States
University of California, San Francisco, San Francisco, California 94122 United States
Abramson Cancer Center, Philadelphia, Pennsylvania 19104 United States
MD Anderson Cancer Center, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: 1. Histologically confirmed invasive lobular carcinoma. Mixed lobular/ductal cancer is allowed. 2. Age \>=18 years 3. Any receptor subtype. 4. Ability to understand a written informed consent document, and the willingness to sign it. Exclusion Criteria: 1. Stage I-III breast cancer. 2. Lack of lobular histology on tumor biopsy. 3. Other active cancer (prior treated cancer with no current evidence of disease is allowed).
Conditions Cervical Cancer, Breast Cancer, Colon Ca...
Phase PHASE1
Enrollment 48
Locations 8 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: ²¹²Pb-DOTAM-GRPR1 — ²¹²Pb-DOTAM-GRPR1 is a radioimmunoconjugate comprised of ²¹²Pb, the metal chelator DOTAM (1,4,7,10-Tetrakis(carbamoylmethyl)-1,4,7,10- tetraazacyclododecane) and a GRPR-targeted antagonist.

Primary Outcomes

  • To determine the Recommended Phase 2 Dose (RP2D) of ²¹²Pb-DOTAM-GRPR1 (14 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2022-12-22
Completion: 2032-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 48 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Orano Med Theranostics, SAS
Contact Information
Study Contact:
Orano Med LLC
469-638-0744
clinicaltrials@oranomed.com
David Bushness, MD
University of Iowa Health Care
859-323-7628
UK Markey Cancer Center
Interventions
  • Drug: ²¹²Pb-DOTAM-GRPR1 — ²¹²Pb-DOTAM-GRPR1 is a radioimmunoconjugate comprised of ²¹²Pb, the metal chelator DOTAM (1,4,7,10-Tetrakis(carbamoylmethyl)-1,4,7,10- tetraazacyclododecane) and a GRPR-targeted antagonist.
Study Locations (8 sites)
Northwestern University Robert H Lurie Medical Research, Chicago, Illinois 60611 United States
University of Iowa Health Care, Iowa City, Iowa 52242 United States
UK Markey Cancer Center, Lexington, Kentucky 40536 United States
Advanced Molecular Imaging and Therapy, Glen Burnie, Maryland 21061 United States
United Theranostics - Chesapeake, Glen Burnie, Maryland 21061 United States
Nebraska Cancer Specialists (Midwest Cancer Center - Legacy), Omaha, Nebraska 68130 United States
XCancer Omaha / Urology Cancer Center, Omaha, Nebraska 68130 United States
University of Pittsburg Medical Center (UPCM), Pittsburgh, Pennsylvania 15219 United States
Eligibility Criteria
1. Adult participants (age ≥ 18 years old) with any of the following advanced or metastatic solid tumors (documented history of histologically confirmed diagnosis): 1. Metastatic castration-resistant prostate cancer (mCRPC) including neuroendocrine prostate cancer (NEPC) (enrolled only in SAD and MAD Q6W) 2. HR+/HER2- breast cancer (estrogen receptor/ER expression \>10% of tumor cell nuclei stain, regardless of progesterone receptor/PgR expression); HER2-negative including HER2-low (as per relevant ASCO/CAP guidelines) 3. Colorectal cancer 4. Cervical cancer 5. Non-small-cell lung cancer (NSCLC) 6. Recurrent glioblastoma (only enrolled in MAD Q4W cohorts) with evidence of recurrent disease (RD) demonstrated by disease progression using modified Response Assessment in Neuro-Oncology (RANO 2.0) criteria. Note: If surgery is performed for GBM recurrence, pre-surgery MRI will be used for confirmation of RD and residual and measurable disease post-surgery is not required but surgery must have confirmed the recurrence diagnosis by MRI. 2. Capable of giving signed informed consent 3. All participants must have progressed on at least 2 prior systemic therapies, except for recurrent GB 4. For participants with mCRPC: Prior orchiectomy and/or ongoing androgen deprivation therapy and a castrate level of serum testosterone (\<50 ng/dL or \<1.7 nmol/L) 5. Presence of at least 1 measurable lesion per RECIST 1.1 as assessed by the Investigator (not applicable for GBM). At least 1 identified measurable lesion must show GRPR uptake in 203Pb-DOTAM-GRPR1 SPECT/CT (uptake greater than that of the background) as assessed by the Investigator. 6. For participants with prostate cancer that do not have measurable soft tissue disease, 203Pb-DOTAM-GRPR1 uptake in bone lesions \> uptake in background is acceptable for eligibility. 7. Eastern Cooperative Oncology Group (ECOG) status 0-1. Participants with ECOG status of 2 may be approved on a case-by-case basis in discussion with the Sponsor. 8. Adequate bone marrow, hepatic, and renal function, as assessed by the following laboratory requirements: 1. White blood cell (WBC) ≥3000/ mm3 (≥ 3 x 109/L) 2. Absolute neutrophil count (ANC) ≥1500/mm3 (≥1.5 x 109/L) 3. Platelets ≥100,000/mm3 (≥ 100 x 109/L) 4. Hemoglobin (Hb) ≥9.0 g/dL 5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3x upper limit of normal (ULN) or ≤ 5 x ULN in the presence of liver metastases 6. Total bilirubin: ≤1.5 x ULN, except if documented history of Gilbert's disease who are eligible if total bilirubin ≤ 3 x ULN 7. Adequate renal function defined by creatinine clearance (CLCR) ≥ 60 mL/min calculated as follows: CLCR = eGFR in ml/min/1.73 m2 calculated by the Modified Diet in Renal Disease (MDRD) x participant body surface area (BSA) in m2 ÷ 1.73 8. Serum amylase and/or lipase ≤1.5 x ULN 9. For women of childbearing potential (WOCBP) and men with partners of childbearing potential: be willing to use highly effective methods of contraception or sexual abstinence, if part of participant's lifestyle, throughout the study and for 7 months for WOCBP, 4 months for men after the last \[212Pb\]Pb-DOTAM-GRPR1 administration or for 10 days following \[203Pb\]Pb-DOTAM-GRPR1 administration and participant is not proceeding to 212Pb-DOTAM-GRPR1 treatment, as outlined in protocol. Participants with Recurrent Glioblastoma: 10. Having first or second glioblastoma recurrence, after standard therapy that includes prior radiation therapy (RT) and at least 12 weeks from completion of RT prior to first administration of 212Pb-DOTAM-GRPR1. In case surgery has been performed for GBM recurrence, the surgery has to be completed at least 4 weeks prior to 212Pb-DOTAM-GRPR1 treatment start, with post-surgery recovery without any complications related to surgical procedure. 11. Presence of 203Pb-DOTAM-GRPR1 uptake by SPECT/CT scan in the tumor lesion(s). 12. Presence of Gadolinium enhancement in the MRI in the tumor lesion(s) shown at the time of diagnosis of tumor recurrence.
Conditions Cancer, Cancer (Colon Cancer, Breast Can...
Phase NA
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this research study is to look at how live, online group exercise compares to recorded videos for helping increase physical activity levels, improve physical fitness and quality of life, and reduce loneliness among those living with and beyond cancer. The following aims have been established for this study: * Aim 1: Examine the effect of a group-based videoconference physical activity (PA) intervention on moderate to vigorous physical activity \[MVPA\] (i.e., aerobic and resistance exercise). * Aim 2: Examine the effect of the intervention on additional health-related outcomes including physical fitness (i.e., aerobic endurance, muscular strength), and quality of life at both timepoints. * Aim 3: Explore potential mediators and moderators of intervention effects. We will examine mediators (e.g., self-efficacy, outcome expectations, group cohesion) and moderators (e.g., age, cancer stage, neighborhood walkability) of the intervention on MVPA. * Exploratory Aim: Determine whether a group-based videoconference PA intervention reduces loneliness among cancer survivors. Researchers will randomize participants into one of two guided exercise groups that are 12-weeks long in duration. Participants will be asked to complete online fitness assessments and surveys as well as wear a physical activity monitor device and watch a few times throughout the study. The whole study is 9-months long in duration with a 6-month free-living period where no study activities will take place.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Virtually Supervised Exercise Sessions — The 12-week intervention will consist of supervised exercise sessions twice per week, and PA behavior change discussion sessions twice per month (bi-weekly) throughout the study for a total of five sessions (Week 2, 4, 6, 8 and 10). Exercise and PA behavior change discussion sessions will be informed by social cognitive theory, operationalize several BCT's, and include group dynamics-based strategies to enhance group cohesion. Exercise sessions will take place twice per week, lasting approximately one hour.
  • Behavioral: Asynchronous Group — The comparator will be an "unsupported intervention",128 which will use the same technology and provide the same content as the intervention but subtract the human components. Participants in the control group will receive access to pre-recorded (i.e., asynchronous) videos of the exercise and discussion sessions. The exercise videos will follow the same format as those in the intervention (i.e., instructor led, circuit-style aerobic and resistance exercises). Discussion sessions will operationalize the same BCT's using PowerPoint slides. Comparator arm participants will receive instructions on how to access these videos via a unique participant login to a secure website, Canvas, the same recommendations to achieve PA guidelines, and the same home-based exercise equipment (along with instructions for use).

Primary Outcomes

  • Change in accelerometer measured moderate to vigorous physical activity from baseline to 3- and 6-month follow-up (Assessed at baseline, 3-and 6-month follow-up)
  • Change in self-reported moderate-to-vigorous intensity physical activity from baseline to 3 and 6 month follow-up (Assessed at baseline, 3 and 6-month follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-06
Completion: 2030-03-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Colorado State University
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Heather J Leach, PhD (PRINCIPAL_INVESTIGATOR) - Colorado State University
Contact Information
Study Contact:
Heather J Leach, PhD
(970) 491-8951
heather.leach@colostate.edu
Elena M Lancioni, MPH
elena.lancioni@colostate.edu
Elena Lancioni
970-491-4653
patplab@colostate.edu
Human Performance Clinical Research Lab
Interventions
  • Behavioral: Virtually Supervised Exercise Sessions — The 12-week intervention will consist of supervised exercise sessions twice per week, and PA behavior change discussion sessions twice per month (bi-weekly) throughout the study for a total of five sessions (Week 2, 4, 6, 8 and 10). Exercise and PA behavior change discussion sessions will be informed by social cognitive theory, operationalize several BCT's, and include group dynamics-based strategies to enhance group cohesion. Exercise sessions will take place twice per week, lasting approximately one hour.
  • Behavioral: Asynchronous Group — The comparator will be an "unsupported intervention",128 which will use the same technology and provide the same content as the intervention but subtract the human components. Participants in the control group will receive access to pre-recorded (i.e., asynchronous) videos of the exercise and discussion sessions. The exercise videos will follow the same format as those in the intervention (i.e., instructor led, circuit-style aerobic and resistance exercises). Discussion sessions will operationalize the same BCT's using PowerPoint slides. Comparator arm participants will receive instructions on how to access these videos via a unique participant login to a secure website, Canvas, the same recommendations to achieve PA guidelines, and the same home-based exercise equipment (along with instructions for use).
Study Locations (1 sites)
Human Performance Clinical Research Lab, Fort Collins, Colorado 80523 United States
Eligibility Criteria
Inclusion Criteria: * Able to speak/read English, * Diagnosed with any type of cancer within the last 5 years * Completed primary or adjuvant treatment (i.e., chemotherapy, radiation therapy, surgery) with no planned treatment within the next nine months. This does not include long-term or chronic therapies such as anti-hormone or targeted therapies (e.g., aromatase inhibitor, androgen deprivation therapy, immunotherapies) Exclusion Criteria: * Existing participation in ≥150 minutes per week of at least moderate intensity aerobic exercise * Known contraindications for non-medically supervised moderate or greater intensity exercise (e.g., uncontrolled hypertension, inability to walk without an assistive device) * Current or planned participation in another structured program or intervention intended to encourage participation in exercise or physical activity.